【Goldman Sachs】【20220807】Hypothalamic obesity transforms opportunity for Imcivree; Upgrade to Buy, $28 PT-21页

Goldman Sachs 卫生和社会工作 2022年 PDF 2.15 MB

RYTM Imcivree Pharmaceuticals Hypothalamic Obesity Biotech